UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and in the area of immunology on allergies, bone loss disorders, Crohn’s disease, rheumatoid arthritis and Systemic lupus erythematosus. UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. UCB also has a selective presence in primary care. The Company, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. As of December 31, 2008, UCB SA had a number of wholly owned subsidiaries in the United States, Canada, Europe, Asia, South America and Australia.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Network Biosystems develops high throughput DNA sequencing systems with applications in the personalized medicine, forensics, drug discovery, and security arenas. The company blends nanotechnology and mircrofluidics to achieve its DNA analysis. Its sequencing systems were conceived at MIT's Whitehead Institute. The company is in the developmental stage and is pursuing a variety of commercial applications including manufacturing a rugged portable STR analysis and identification in the forensics field and on site screening of large numbers for use by homeland security.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

Pfizer decided to put a Cork in it, the pharmaceutical giant made Ireland one of the world's largest manufacturers and exporters of pharmaceuticals. Pfizer Ireland Pharmaceuticals is part of the Pfizer Global Manufacturing division. Parent company Pfizer began operating in Ireland in 1969 with a citric acid manufacturing plant and now operates about a dozen Irish plants. Its manufacturing facilities are involved in the development, formulation, and bulk manufacture of human pharmaceuticals (especially cardiovascular drugs) and animal health care products, as well as sterile pharmaceutical products and active pharmaceutical ingredients.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.

Carma Laboratories, Inc. company was founded by Alfred Woelbing, who developed the formula for Carmex in 1937 as a treatment for his own cold sores. Carma Laboratories wants to make it easier for you to smile and sit. The family-owned-and-operated company is most famous for its retro yellow-lidded vials of Carmex lip balm. The company also makes Am-Ren, a zinc-oxide based diaper rash ointment, and LANEX hemorrhoid ointment to soothe cracked and painful tissues elsewhere. Once sold mostly in the Midwest and the ski areas of the Rockies, Carmex soothes lips in all 50 states, Canada, Australia, and Europe.

Response Genetics Inc. company was founded in 1999 and is headquartered in Los Angeles, California. Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suite, which comprises KRAS Mutation and EGFR Amplification tests. The KRAS Mutation test identifies tumors that have low probability of response to EGFR-directed therapy. The EGFR Amplification test assesses the probability of benefit from EGFR-directed therapy. The company also offers ResponseDX: Colon test suite that includes ERCC1, KRAS Mutation, and TS tests. The ERCC1 test is a test for the probability of response to platin-based therapies and the analysis of RRM1 tests for the probability of response to gemcitabine-based therapies. The TS test measures the probability of response to 5-fluorouracil -based chemotherapy. In addition, Response Genetics, Inc. is developing tests of other types of cancer that identify genetic profiles of tumors that recur after surgery. The company has collaboration agreements with Shanghai BioChip Company, Ltd. to provide pharmacogenomic testing services in China using the company's RGI-1 extraction technology; and Hitachi Chemical Co., Ltd. to use its techniques to extract genetic information from formalin-fixed paraffin-embedded tissue samples. It offers its services in the areas of oncology for oncologists, hospitals, and physician offices through the sales force.

Cardiovascular Systems, Inc. company was founded in 1989 and is based in Saint Paul, Minnesota. Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing interventional treatment systems for vascular disease. Its primary product, the Diamondback 360°, is a minimally invasive catheter system for the treatment of peripheral arterial disease and a range of plaque types in leg arteries. The Diamondback 360° consists of a single-use catheter that travels over its proprietary ViperWire Guide Wire. The system is used in conjunction with a reusable external control unit.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.